Analyst Research Report Snapshot

Title:

ABLYNX - PFIZER’S DATA AND DECISION

Price:

$10.00

Provider:

Edison Investment Research

Date:

28 Feb 2011

Pages:

10

Type:

AcrobatPDF

Companies referenced:

PFE.N NOVN.VX

Available for Immediate Download
Summary:

The potential of Ablynx’s Nanobodies should become clearer during 2011. The results from proof-of-concept studies with two Nanobodies (ATN-103 in rheumatoid arthritis and ALX-0081 in acute coronary syndrome) could be reported this year. The results with ATN-103 are particularly important as they could persuade Pfizer to start a Phase III trial with this drug. By the end of 2011, one Nanobody could be in Phase III, three in Phase II (one with proof-of-concept data) and four in Phase I (three may enter the clinic in 2011).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.